Alpha-1 antitrypsin - Kamada

Drug Profile

Alpha-1 antitrypsin - Kamada

Alternative Names: A1AT; A1PI; AAT; AAT-IH; AAT-IV; Alpha-1 Antitrypsin; Alpha-1-Antiproteinase; alpha-1-proteinase inhibitor; ALPHA.1-PROTEINASE INHIBITOR HUMAN; Aralast; G1-AAT IV; Glassia; Inhaled-AAT; IV AAT; Kamada-API; Prolastin-C

Latest Information Update: 21 Jun 2017

Price : $50

At a glance

  • Originator Kamada
  • Developer Kamada; Shire
  • Class Acute-phase proteins; Alpha globulins; Anti-inflammatories; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
  • Mechanism of Action Immunomodulators; Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease; Bronchiectasis; Alpha 1-antitrypsin deficiency; Cystic fibrosis; Type 1 diabetes mellitus
  • New Molecular Entity No

Highest Development Phases

  • Marketed Alpha 1-antitrypsin deficiency
  • Phase II/III Graft-versus-host disease; Type 1 diabetes mellitus
  • Phase II Bronchiectasis; Cystic fibrosis; Lung transplant rejection

Most Recent Events

  • 07 Jun 2017 Baxalta suspends patient enrolment in a phase II/III trial in Graft-versus-host disease (Adjunctive treatment) due to pipeline prioritisation and slow recruitment rate in its ongoing phase II/III study in USA (IV)
  • 07 Jun 2017 Kamada intends to resume clinical development programme for Graft-versus-host disease in USA and EU
  • 07 Jun 2017 Shire halts part I of a phase II/III trial for Graft-versus-host disease in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top